Wah Ng - Haw Par Deputy General Manager-Manufacturing of Healthcare
| HAWPY Stock | USD 28.64 0.00 0.00% |
Executive
Mr. Ng Wah Tong is Deputy General Manager Manufacturing of Healthcare of Haw Par Corporation Ltd. He joined Haw Par Healthcare in 2009 as Production Manager, promoted to Manufacturing Manager in 2012. Promoted to present position in 2013. Holds a BS from the National University of Singapore. since 2013.
| Tenure | 11 years |
| Phone | 65 6337 9102 |
| Web | https://www.hawpar.com |
Haw Par Management Efficiency
Haw Par's management efficiency ratios could be used to measure how well Haw Par manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gottlieb Keller | Roche Holding Ltd | 64 | |
| Michael Varney | Roche Holding Ltd | 60 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Verena Briner | Novartis AG ADR | 64 | |
| M Tubau | Grifols SA ADR | N/A | |
| Felix Ehrat | Novartis AG ADR | 60 | |
| Vicente Torre | Grifols SA ADR | 63 | |
| Victoria Whyte | GlaxoSmithKline PLC ADR | N/A | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Noriaki Yamamoto | Santen Pharmaceutical Co | N/A | |
| John Tsai | Novartis AG ADR | 54 | |
| Masamichi Sato | Santen Pharmaceutical Co | N/A | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Andreas Panayiotou | Pfizer Inc | N/A | |
| Susanne Fiedler | Organon Co | 56 | |
| David Epstein | Novartis AG ADR | 53 | |
| Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Charlotte PamerWieser | Novartis AG ADR | N/A | |
| George Gunn | Novartis AG ADR | 63 | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
Management Performance
| Return On Equity | 0.0424 | |||
| Return On Asset | 0.0063 |
Haw Par Leadership Team
Elected by the shareholders, the Haw Par's board of directors comprises two types of representatives: Haw Par inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haw. The board's role is to monitor Haw Par's management team and ensure that shareholders' interests are well served. Haw Par's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haw Par's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sat Khattar, Independent Director | ||
| Siew Shiu, Acting Group Internal Audit Manager | ||
| Meng Kwek, Regional General Manager of Underwater World Singapore Pte Ltd / Haw Par Leisure Pte Ltd | ||
| Swee Sim, Non-Executive Independent Director | ||
| Cho Wee, Non-Executive, Non Independent Chairman of the Board | ||
| Chua Keeth, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
| Wah Ng, Deputy General Manager-Manufacturing of Healthcare | ||
| Ee Wee, CEO and President Director, Member of Investment Committee, CEO of Haw Par Healthcare Limited and Acting President of Haw Par Healthcare Limited | ||
| Mui Kow, Senior Manager-Quality & Regulatory Affairs of Healthcare | ||
| Brian Loo, Group Mang | ||
| Peter Chew, Deputy General Manager of Underwater World Singapore Pte Ltd | ||
| Kia Chew, Non-Executive Independent Director | ||
| Choon Chew, Non-Executive Independent Director | ||
| Tang Lee, Mang Communications | ||
| Tang Chow, Human Director | ||
| Anthony Chang, Curator of Underwater World Singapore Pte Ltd | ||
| Suan Lee, Non-Executive Independent Director | ||
| Kun Chiew, Group Sec | ||
| Ah Han, Executive Director, Member of Investment Committee, General Manager of Haw Par Healthcare Limited and Director of Haw Par Healthcare Limited | ||
| Hiang Gn, Non-Executive Independent Director | ||
| Seok Lim, CFO and Company Secretary | ||
| Sien Tarn, General Manager - Corporate Development & Property Division | ||
| Sung Whang, General Manager of Underwater World Pattaya Ltd | ||
| Soo Hwang, Non-Executive Independent Director | ||
| Bee Goh, Director & General Manager - Manufacturing of Haw Par Healthcare Limited | ||
| Eechao Wee, Non-Executive Non Independent Director | ||
| Say Chow, Group Finance Controller | ||
| Jasmin Hong, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
| Kay Lee, Company Secretary |
Haw Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Haw Par a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0424 | |||
| Return On Asset | 0.0063 | |||
| Profit Margin | 0.79 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | (701.58 M) | |||
| Shares Outstanding | 55.34 M | |||
| Price To Earning | 21.33 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 10.01 X | |||
| Revenue | 141.18 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haw Par. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Haw Pink Sheet analysis
When running Haw Par's price analysis, check to measure Haw Par's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haw Par is operating at the current time. Most of Haw Par's value examination focuses on studying past and present price action to predict the probability of Haw Par's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haw Par's price. Additionally, you may evaluate how the addition of Haw Par to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |